Fierce Biotech reports that AZ's zibotentan failed to meet its endpoints in another late stage clinical trial - this time for prostate cancer. The plug was pulled on the trial when researchers' concluded the drug would not increase survival rates beyond standard therapy in this patient class.
AZ is taking one more (and its last) bite at the apple in testign zibotentan plus chemotherapy in patients with metastatic prostate cancer. This is still considered a long shot - and all hopes of this drug competing head to head with Dendreon's Provenge are gone.
AZ looks like it can add zibotentan to the list of late stage failures to accompany Recentin (colon cancer) and Vandetanib (NSCLC). Cancer treatments failures continue to take a heavy toll in the industry's R&D pipeline - especially in phase III vs standard therapies.
Posted by Bruce Lehr Feb 7th 2011.